Pfizer Animal Health announced plans last week to acquire two livestock genomics companies: Australia-based Catapult Genetics, Pty., Ltd., and Bovigen, LLC, the Louisiana-based company that markets Catapult’s products and services in North America.

The acquisitions are expected to close by the end of this month.

The two companies will continue to market products and services to their existing customers as well as Pfizer Animal Health customers. Current genetic tests are focused on productivity and carcass quality, according to a company release.

Pfizer Animal Health President Juan Ramon Alaix says future genetic tests might allow producers to better predict disease in individual animals, helping veterinarians and producers target medicine to livestock that need it most.